BACKGROUND: Previous randomized studies have reported conflicting results on the efficacy of omega-3 fatty acids in preventing atrial fibrillation (AF) recurrences after cardioversion. OBJECTIVE: A systematic review and meta-analysis of the role of omega-3 fatty acids in the prevention of atrial fibrillation recurrences after cardioversion was conducted. METHODS: PubMed, Cochrane Library, Elsevier, Science Online database were searched up to the end of January 2012 to identify all of the studies in human subjects that reported the effects of omega-3 fatty acids on the prevention of atrial fibrillation recurrences after cardioversion. RESULTS: Overall, omega-3 fatty acids had no significant effect on the prevention of AF recurrences after cardioversion (OR: 0.63,95% CI 0.35-1.13; p=0.12). The heterogeneity among the studies was significant (p=0.01, I(2)=66%). Subgroup analysis showed that by administering omega-3 fatty acids at least 4 weeks prior to cardioversion and continuing thereafter, the recurrence rate of AF is significantly low (OR: 0.39, 95% CI 0.25-0.61; p<0.0001). CONCLUSION: In the subgroup administered omega-3 fatty acids at least 4 weeks prior to cardioversion and continued thereafter, the recurrence rate of AF was significantly low. More double-blind, randomized, placebo-controlled, multicenter studies with high quality and longer follow-up periods are needed to affirm our conclusion.
BACKGROUND: Previous randomized studies have reported conflicting results on the efficacy of omega-3 fatty acids in preventing atrial fibrillation (AF) recurrences after cardioversion. OBJECTIVE: A systematic review and meta-analysis of the role of omega-3 fatty acids in the prevention of atrial fibrillation recurrences after cardioversion was conducted. METHODS: PubMed, Cochrane Library, Elsevier, Science Online database were searched up to the end of January 2012 to identify all of the studies in human subjects that reported the effects of omega-3 fatty acids on the prevention of atrial fibrillation recurrences after cardioversion. RESULTS: Overall, omega-3 fatty acids had no significant effect on the prevention of AF recurrences after cardioversion (OR: 0.63,95% CI 0.35-1.13; p=0.12). The heterogeneity among the studies was significant (p=0.01, I(2)=66%). Subgroup analysis showed that by administering omega-3 fatty acids at least 4 weeks prior to cardioversion and continuing thereafter, the recurrence rate of AF is significantly low (OR: 0.39, 95% CI 0.25-0.61; p<0.0001). CONCLUSION: In the subgroup administered omega-3 fatty acids at least 4 weeks prior to cardioversion and continued thereafter, the recurrence rate of AF was significantly low. More double-blind, randomized, placebo-controlled, multicenter studies with high quality and longer follow-up periods are needed to affirm our conclusion.
Authors: Hassan Fares; Carl J Lavie; James J DiNicolantonio; James H O'Keefe; Richard V Milani Journal: Curr Atheroscler Rep Date: 2014-02 Impact factor: 5.113
Authors: Silvia Lorente-Cebrián; André G V Costa; Santiago Navas-Carretero; María Zabala; J Alfredo Martínez; María J Moreno-Aliaga Journal: J Physiol Biochem Date: 2013-06-22 Impact factor: 4.158
Authors: Javier Mariani; Hernán C Doval; Daniel Nul; Sergio Varini; Hugo Grancelli; Daniel Ferrante; Gianni Tognoni; Alejandro Macchia Journal: J Am Heart Assoc Date: 2013-02-19 Impact factor: 5.501
Authors: Jennifer E Enns; Azadeh Yeganeh; Ryan Zarychanski; Ahmed M Abou-Setta; Carol Friesen; Peter Zahradka; Carla G Taylor Journal: BMC Cardiovasc Disord Date: 2014-05-31 Impact factor: 2.298
Authors: Georgios A Christou; Konstantinos A Christou; Panagiotis Korantzopoulos; Evangelos C Rizos; Dimitrios N Nikas; John A Goudevenos Journal: Int J Mol Sci Date: 2015-09-22 Impact factor: 5.923